KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Income from Continuing Operations for 15 consecutive years, with 111548000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 233.17% year-over-year to 111548000.0, compared with a TTM value of 313752000.0 through Dec 2025, up 212.8%, and an annual FY2025 reading of 313752000.0, up 212.8% over the prior year.
  • Income from Continuing Operations was 111548000.0 for Q4 2025 at Alnylam Pharmaceuticals, down from 292683000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 292683000.0 in Q3 2025 and bottomed at 405920000.0 in Q3 2022.
  • Average Income from Continuing Operations over 5 years is 119431350.0, with a median of 155985500.0 recorded in 2023.
  • Peak annual rise in Income from Continuing Operations hit 362.33% in 2025, while the deepest fall reached 327.66% in 2025.
  • Year by year, Income from Continuing Operations stood at 258460000.0 in 2021, then rose by 19.72% to 207493000.0 in 2022, then surged by 33.55% to 137870000.0 in 2023, then surged by 39.24% to 83763000.0 in 2024, then surged by 233.17% to 111548000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ALNY at 111548000.0 in Q4 2025, 292683000.0 in Q3 2025, and 72228000.0 in Q2 2025.